Company news
Rallybio Corporation news in 2022
Rallybio Corporation's news releases, calls and decks from 2022, newest first.
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
December 14, 2022
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
November 30, 2022
Rallybio Announces Proposed Public Offering
November 9, 2022
Rallybio Announces Pricing of $50 Million Public Offering
November 9, 2022
Rallybio Reports Third Quarter 2022 Financial Results
November 6, 2022
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
November 6, 2022
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
September 27, 2022
Rallybio Reports Second Quarter 2022 Financial Results
August 7, 2022
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
August 1, 2022
Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer
June 1, 2022
Rallybio Reports First Quarter 2022 Financial Results
May 9, 2022
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
May 9, 2022
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
April 3, 2022
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
March 14, 2022
Decks in 2022
- Investor Presentation (March 2022)
Investor deck · 29 slides · Mar 7, 2022